---
schema_version: "secwatch.filing_event.v1"
accession: "0001753926-24-001960"
form_type: "8-K12G3"
ticker: "PTHS"
cik: "0001919246"
company_name: "Pelthos Therapeutics Inc."
filed_at: "2024-11-19T23:59:59+00:00"
generated_at: "2026-05-29T22:43:37.252900+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Channel Therapeutics completes reincorporation from Delaware to Nevada; stockholder rights change

## Summary
- Chromocell Therapeutics merged into wholly-owned Nevada subsidiary Channel Therapeutics; all shares converted 1:1.
- Company name changed to Channel Therapeutics Corporation; ticker remains CHRO on NYSE American.
- Governing law shifts from DGCL to NRS; stockholder rights may differ as described in proxy statement filed Sept 26, 2024.
- Existing directors and officers remain; all prior liabilities assumed by Nevada corporation.
- Indemnification agreements updated to reflect Nevada law.

## SEC filing metadata
- accession: 0001753926-24-001960
- form_type: 8-K12G3
- ticker: PTHS
- cik: 0001919246
- company_name: Pelthos Therapeutics Inc.
- filed_at: 2024-11-19T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 1.01, 2.03, 3.03, 5.02, 5.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1919246/000175392624001960/0001753926-24-001960-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1919246/000175392624001960/g084563_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001753926-24-001960
- JSON: https://secwatch.observer/filing/0001753926-24-001960.json
- Plain text: https://secwatch.observer/filing/0001753926-24-001960.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.